Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 12162870
Anticancer compounds
granted -
US 12163148
Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
granted -
US 12162912
Proteins for blocking neurotransmitter release
granted -
US 12162937
Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel
granted -
US 12161621
Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
granted -
US 12162950
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
granted -
US 12156877
Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
granted -
US 12156893
Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
granted -
US 12156908
Virus like nanoparticle compositions and methods thereof
granted -
US 12156912
Methods and compositions for inhibiting diseases of the central nervous system
granted -
US 12157778
Peptides for activation of cell signaling in osteoprogenitor cells
granted -
US 12150956
Trace element compositions, methods of making and use
granted -
US 12152270
Neurotransmitter transport in probiotics
granted -
US 12152071
EGFL6 specific monoclonal antibodies and methods of their use
granted -
US 12151062
Compositions and devices to administer pharmaceutical compositions nasally
granted -
US 12151998
Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
granted -
US 12150957
Trace element compositions, methods of making and use
granted -
US 12145925
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
granted -
US 12144843
Methods and compositions for modulating myofibroblast activities
granted -
US 12145944
Imidazopyrimidines as EED inhibitors and the use thereof
granted -
US 12146139
Oligonucleotide interference treatments of prostate cancer
granted -
US 12144826
Methods of treating EGFRvIII expressing glioblastomas
granted -
US 12144800
Inhibiting germination of Clostridium perfringens spores to reduce necrotic enteritis
granted -
US 12144828
Human Kynureninase enzymes and uses thereof
granted -
US 12138274
Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
granted -
US 12139764
Systems and methods for characterizing and treating breast cancer
granted -
US 12139531
Compositions and methods useful in promoting milk production
granted -
US 12139470
Trioxolane agents
granted -
US 12134609
Quinoline cGAS antagonist compounds
granted -
US 12134648
Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
granted -
US 12134651
Anti-Ryk antibodies and methods of using the same
granted -
US 12133924
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 12128015
APE/REF1 inhibitors for the treatment of cancer
granted -
US 12121542
BCMA chimeric antigen receptor based on single domain antibody and use thereof
granted -
US 12121567
Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase
granted -
US 12121288
Combination tumor treatment
granted -
US 12121525
Methods for treating GI syndrome and graft versus host disease
granted -
US 12121580
Antibacterial photodynamic therapy using copper-cysteamine nanoparticles
granted -
US 12123015
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 12115183
Synthetic melanin nanoparticles and uses thereof
granted -
US 12116423
Ang (1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 12116637
Compositions and methods for detecting and treating high grade subtypes of uterine cancer
granted -
US 12116375
Compositions and methods for treating cancer
granted -
US 12116597
Autophagy as a therapeutic target for intracranial aneurysm
granted -
US 12116604
Transposase polypeptides and uses thereof
granted -
US 12115149
Formulations, methods, kits, and dosage forms
granted -
US 12109239
Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof
granted -
US 12109224
USB1 directed regulation of miRNAs related hematopoietic differentiation and affected in multiple forms of leukemia
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory